420 related articles for article (PubMed ID: 25440605)
1. GD2-targeted immunotherapy and radioimmunotherapy.
Dobrenkov K; Cheung NK
Semin Oncol; 2014 Oct; 41(5):589-612. PubMed ID: 25440605
[TBL] [Abstract][Full Text] [Related]
2. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Fleurence J; Fougeray S; Bahri M; Cochonneau D; Clémenceau B; Paris F; Heczey A; Birklé S
J Immunol Res; 2017; 2017():5604891. PubMed ID: 28154831
[TBL] [Abstract][Full Text] [Related]
4. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
Voeller J; Sondel PM
J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
[TBL] [Abstract][Full Text] [Related]
5. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
6. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma.
Roth M; Linkowski M; Tarim J; Piperdi S; Sowers R; Geller D; Gill J; Gorlick R
Cancer; 2014 Feb; 120(4):548-54. PubMed ID: 24166473
[TBL] [Abstract][Full Text] [Related]
7. Disialoganglioside GD2 as a therapeutic target for human diseases.
Suzuki M; Cheung NK
Expert Opin Ther Targets; 2015 Mar; 19(3):349-62. PubMed ID: 25604432
[TBL] [Abstract][Full Text] [Related]
8. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
9. Anti-GD2 antibody therapy for GD2-expressing tumors.
Navid F; Santana VM; Barfield RC
Curr Cancer Drug Targets; 2010 Mar; 10(2):200-9. PubMed ID: 20201786
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Strategies for Human IgM Antibodies Directed at Tumor-Associated Ganglioside Antigens: Discoveries Made During the Morton Era and Future Directions.
Jones PC; Irie RF
Crit Rev Oncog; 2016; 21(1-2):75-81. PubMed ID: 27481004
[TBL] [Abstract][Full Text] [Related]
11. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3.
Bernhard H; Karbach J; Strittmatter W; Meyer zum Büschenfelde KH; Knuth A
Int J Cancer; 1993 Sep; 55(3):465-70. PubMed ID: 8375931
[TBL] [Abstract][Full Text] [Related]
12. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
14. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy.
Reisfeld RA; Mueller BM; Handgretinger R; Yu AL; Gillies SD
Prog Brain Res; 1994; 101():201-12. PubMed ID: 8029452
[No Abstract] [Full Text] [Related]
15. Anti-GD2 immunotherapy for neuroblastoma.
Sait S; Modak S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
[TBL] [Abstract][Full Text] [Related]
16.
Zhang Y; Kupferschlaeger J; Lang P; Reischl G; Handgretinger RJ; Fougère C; Dittmann H
J Nucl Med; 2022 Feb; 63(2):205-211. PubMed ID: 34049985
[TBL] [Abstract][Full Text] [Related]
17. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
Perez Horta Z; Goldberg JL; Sondel PM
Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
[TBL] [Abstract][Full Text] [Related]
18. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.
Dobrenkov K; Ostrovnaya I; Gu J; Cheung IY; Cheung NK
Pediatr Blood Cancer; 2016 Oct; 63(10):1780-5. PubMed ID: 27304202
[TBL] [Abstract][Full Text] [Related]
19. In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors.
Ahmed M; Goldgur Y; Hu J; Guo HF; Cheung NK
PLoS One; 2013; 8(5):e63359. PubMed ID: 23696816
[TBL] [Abstract][Full Text] [Related]
20. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
Modak S; Gerald W; Cheung NK
Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
